Edgewise Therapeutics (EWTX) Total Current Liabilities (2020 - 2026)

Edgewise Therapeutics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $22.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $22.5 million, up 6.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.5 million (up 6.76% YoY), and the FY2025 annual result was $27.4 million, up 14.71% from the prior year.
• Total Current Liabilities came in at $22.5 million for Q1 2026 at Edgewise Therapeutics, down from $27.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $27.4 million in Q4 2025 to a low of $9.2 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $16.8 million (2023), against an average of $17.5 million.
• Across the five-year window, Total Current Liabilities surged 106.23% in 2022 and climbed 1.12% in 2023, its largest moves.
• Edgewise Therapeutics' Total Current Liabilities stood at $16.6 million in 2022, then grew by 1.12% to $16.8 million in 2023, then soared by 42.27% to $23.9 million in 2024, then rose by 14.71% to $27.4 million in 2025, then retreated by 17.64% to $22.5 million in 2026.
• The last three Total Current Liabilities figures came in at $22.5 million (Q1 2026), $27.4 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.